PRECIGEN, INC.

PGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2026 Mar 2026 Jun 2025 Mar 2025 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Revenue $55.0M $23.3M $856.0K $1.3M $1.8M $1.9M $1.8M $16.7M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $7.3M $5.6M $11.5M $10.5M
SG&A Expense $22.2M $21.0M $16.1M $12.4M
Operating Income $22.6M $-6.0M $-31.8M $-22.6M $-20.4M $-22.8M $-22.2M $-7.7M
Operating Margin 41.2% -25.8% -3,710.7% -1,685.0% -1,153.6% -1,231.2% -1,257.4% -46.0%
Interest Expense
Pretax Income $20.1M $-7.9M $-26.6M $-54.2M $-20.4M $-22.8M $-22.2M $-7.7M
Income Tax Expense $0 $0 $3.0K $0 $-65.0K $-55.0K $8.0K $-50.0K
Net Income $20.1M $-7.9M $-26.6M $-54.2M $-20.3M $-22.7M $-22.2M $87.4M
Net Margin 36.5% -34.1% -3,112.4% -4,038.3% -1,149.9% -1,228.2% -1,257.9% 522.5%
EPS (Basic) $0.06 $-0.02 $-0.09 $-0.18 $-0.08 $-0.10 $-0.11 $0.44
EPS (Diluted) $0.05 $-0.02 $-0.09 $-0.18 $-0.08 $-0.10 $-0.11 $0.44
Shares Outstanding (Basic) 356.9M 354.3M 296.4M 293.9M 248.0M 229.8M 200.4M 200.7M
Shares Outstanding (Diluted) 413.7M 354.3M 296.4M 293.9M 248.0M 229.8M 200.4M 200.7M
Dividends Per Share
← Newer Page 1 of 7 Older →